Approach to Medication Discontinuation in Bipolar Disorder

Introduction to Discontinuation

The American Academy of Child and Adolescent Psychiatry recommends that a medicated bipolar patient on a mood stabilizer and antipsychotic who wishes to discontinue medication should be strongly counseled against discontinuation, as withdrawal of maintenance therapy is associated with relapse rates exceeding 90% in noncompliant patients versus 37.5% in compliant patients, and if discontinuation is pursued despite counseling, implement a gradual taper over months with intensive monitoring rather than abrupt cessation 1, 2.

Bipolar disorder is a recurrent illness requiring lifelong treatment in most cases, with some individuals needing indefinite therapy when benefits outweigh risks, according to the American Academy of Child and Adolescent Psychiatry 1, 2.
The risk of relapse is extraordinarily high and occurs rapidly, with more than 90% of adolescents who were noncompliant with lithium treatment relapsing, compared to only 37.5% of those who were compliant, as stated by the American Academy of Child and Adolescent Psychiatry 2, 3.

The American Academy of Child and Adolescent Psychiatry suggests that before discontinuing any medication, obtain a detailed history, including previous psychiatric symptoms and their severity, response to current and past medications, and collateral history from previous prescribers 1, 4.
A comprehensive monitoring strategy should be developed before initiating taper, including weekly visits during the initial taper phase and monthly visits for 6-12 months after complete discontinuation, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 4.
The tapering approach should reduce the dose by 25% every 4-8 weeks minimum, with a slower taper for lithium over 3-6 months minimum, according to the American Academy of Child and Adolescent Psychiatry 1, 4.

The American Academy of Child and Adolescent Psychiatry recommends establishing written criteria for medication reinitiation, including specific symptoms that trigger immediate medication restart, emergency contact numbers, and a crisis plan 2, 3.
Mandatory adjunctive interventions include psychoeducation, cognitive-behavioral therapy, and family-focused therapy, as stated by the American Academy of Child and Adolescent Psychiatry 2, 3.

For mood stabilizers (lithium, valproate), lithium withdrawal carries the highest relapse risk and should be tapered most slowly, according to the American Academy of Child and Adolescent Psychiatry 2, 3.
For atypical antipsychotics, monitor for withdrawal dyskinesia or rebound psychosis and continue metabolic monitoring during taper, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 4.